Biologics and targeted therapy for severe refractory asthma
According to Asthma Canada, 3.8-million Canadians suffer from this chronic inflammatory condition and estimates 250,000 have severe asthma. Asthma has entered the era of personalized medicine with therapies that target specific inflammatory pathways in people with severe disease who don’t respond to normal inhaler therapy.